Study on Muscle Growth in Healthy Aging and Sarcopenia Patients Using Testosterone Undecanoate and Placebo

2 1 1

What is this study about?

This clinical trial is focused on understanding how human muscles might remember past exposure to testosterone, a hormone important for muscle growth. The study is particularly interested in conditions like healthy aging and sarcopenia, which is the loss of muscle mass and strength as people age. The trial will also explore issues related to anabolic resistance, which is when muscles do not grow as expected in response to exercise or hormones, and anti-doping concerns in sports.

The study will use two treatments: Nebido, which contains testosterone undecanoate, and a placebo. Participants will be divided into groups, with some receiving the testosterone treatment and others receiving the placebo. The main goal is to see if muscles can grow back to their previous size and strength after stopping testosterone for a while. This will be compared between those who had testosterone before and those who did not.

Participants will undergo a series of tests to measure changes in muscle size, strength, and other characteristics. These tests will include methods like DEXA scans, which are used to measure body composition, and muscle biopsies, which involve taking a small sample of muscle tissue for analysis. The study will also look at how muscle cells change at a genetic level, including changes in DNA methylation, which is a process that can affect how genes are turned on or off. The trial aims to provide insights into how muscles respond to testosterone and how this might be used to improve muscle health in older adults.

1 joining the study

Upon joining the study, you will be asked to provide written informed consent. This confirms your understanding and agreement to participate in the trial.

2 initial assessments

You will undergo initial assessments, which include a medical questionnaire, a physical examination, routine blood tests, and urine samples. These assessments ensure you meet the study’s criteria: being a sedentary male aged 55-70, with morning serum testosterone levels greater than 8 nmol/L, and without any known illnesses or conditions.

3 treatment phase

During the treatment phase, you may receive either a placebo or testosterone undecanoate through an intramuscular injection. The testosterone undecanoate is administered as a solution for injection at a dosage of 1000 mg/4 ml. The frequency and duration of administration will be specified by the study team.

4 monitoring and assessments

Throughout the trial, your progress will be monitored through various assessments. These include measuring changes in fat-free mass, muscle size, and muscle fiber types using techniques like DEXA scans, ultrasound, and muscle biopsies. Additionally, strength, velocity, and power will be evaluated using equipment such as the Keiser leg press machine and isokinetic dynamometry.

5 conclusion of the trial

The trial is expected to conclude by September 30, 2025. At the end of the study, final assessments will be conducted to compare the ability to retrain and enhance muscle size after a period of detraining or testosterone abstinence between the testosterone and placebo groups.

Who Can Join the Study?

Sedentary males – Men who do not engage in regular physical activity.
Aged 55-70 years old.
Have serum testosterone levels greater than 8 nmol/L, measured in the morning. Serum testosterone is the amount of testosterone in the blood.
Do not have any known illness, disease, or other medical conditions.
Have completed a screening process, which includes a medical questionnaire, physical examination, routine blood tests, and urine samples.
Have provided written informed consent, meaning they have agreed to participate in the study after being informed about it.

Who Cannot Join the Study?

Participants must be male. Females cannot participate in this study.
Participants should not be part of a vulnerable population. This means they should not be in a group that needs special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Oslo Universitetssykehus HF	Oslo	Norway
Norges Idrettshoegskole	Oslo	Norway

Other Sites

No sites found in this category

Trial status

Country	Status	Recruitment Start
Norway	Not recruiting	06.08.2024

Trial locations

Investigated drugs:

Testosterone is a hormone that plays a key role in developing and maintaining male physical characteristics. In this clinical trial, testosterone is being used to see if it can help muscles grow bigger and stronger after a period of not using it. The study aims to find out if muscles can “remember” the effects of testosterone and respond better when it is used again after a break.

Healthy aging – Healthy aging refers to the natural process of growing older while maintaining physical and mental well-being. It involves the gradual decline in bodily functions, such as muscle mass and bone density, which can affect mobility and strength. Cognitive functions may also change, with some decline in memory and processing speed. However, healthy aging emphasizes the ability to adapt to these changes and maintain a good quality of life. It is characterized by the absence of significant chronic diseases and the ability to engage in daily activities independently. Social engagement and mental health are also important aspects of healthy aging.

Sarcopenia – Sarcopenia is the progressive loss of muscle mass and strength that occurs with aging. It begins to develop around the age of 30 and accelerates after the age of 60. This condition can lead to decreased mobility, increased risk of falls, and reduced ability to perform daily activities. Muscle fibers shrink and are replaced by fat and fibrous tissue, contributing to weakness. Sarcopenia is influenced by factors such as physical inactivity, poor nutrition, and hormonal changes. It is a major component of frailty in older adults.

Anabolic resistance – Anabolic resistance is the reduced ability of the body to build muscle in response to protein intake or exercise. It is commonly observed in older adults and can contribute to muscle loss and weakness. This condition is characterized by a diminished response of muscle protein synthesis to dietary protein and physical activity. Factors contributing to anabolic resistance include aging, inflammation, and hormonal changes. It can lead to difficulties in maintaining muscle mass and strength, impacting overall physical function. Anabolic resistance is a key factor in the development of sarcopenia.

Trial ID:

2023-507815-37-00

NCT ID:

NCT05964920

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Muscle Growth in Healthy Aging and Sarcopenia Patients Using Testosterone Undecanoate and Placebo

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?